ClinicalTrials.gg
CompletedNCT03462927Updated Dec 24, 2019Results posted

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

A Phase 2 interventional study of MC2-01 Cream and CAL/BDP combination in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-24.

Sponsored by MC2 Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
30th of 47
63 · median 200
Started
2018
with 2 others
Phase 2
9 of 47
none open now
Registered
35th of 47
by date
Lead sponsor
4 of 47
MC2 Therapeutics

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 30th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 2, and was the 35th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene [CAL]/betamethasone [BDP] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.

Read the detailed description

The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines. In this trial, the MC2-01 cream will be compared to a marketed calcipotriene [CAL]/betamethasone dipropionate [BDP] ointment. The purpose of the trial, is to determine the pharmacokinetic parameters of MC2-01 cream and the comparator under maximum use conditions.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have provided written .
  • Generally healthy males or non-pregnant females, of any race or ethnicity, who are at least 18 years of age at the time of screening.
  • At Visit 1/Day 0, have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6 months duration involving scalp and body (trunk and/or limbs) that is amenable to topical treatment with a maximum of 100 g of trial medication per week.
  • Have a Physician's Global Assessment [PGA] of severity of at least moderate on the trunk, limbs and/or scalp, at Visit 1/Day 0.
  • Have a treatment area between 20% and 30% of the body surface area [BSA] on the trunk, limbs and/or scalp, excluding psoriatic lesions on the face, genitals, and intertriginous areas, at Visit 1/Day 0.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of unstable forms of psoriasis
  • Other inflammatory skin disease in the treatment area
  • Pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
  • Planned exposure to natural or artificial sunlight
  • Phototherapy and ultraviolet B radiation within 4 weeks prior to Visit 1/Baseline and during the trial;
  • Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders;
  • Oral calcium supplements, vitamin D supplements, bisphosphonates or calcitonin within 4 weeks prior to Visit 1/Day 0 during the trial period.
  • Planned initiation of, or changes to concomitant medication that could affect calcium metabolism during the trial;
  • Planned initiation of, or changes to, concomitant estrogen therapy during the trial;
  • Strong systemic cytochrome P450 3A4 (CYP 3A4) inhibitors within 4 weeks prior to Vist 1/Day 0 and during the trial period;
  • Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Day 0 and during the trial period;
  • Systemic treatment with biological therapies
  • Initiation of, or expected changes to, concomitant medication that may affect psoriasis during the trial period;
  • Depression and endocrine disorders known to affect cortisol levels or HPA axis integrity, non-nocturnal sleep patterns
  • Systemic medication that suppresses the immune system within 4 weeks prior to the Visit 1/Day 0 and during the trial period;
  • Clinical signs of skin infection with bacteria, viruses, or fungi;
  • Known [HIV] infection;
  • Known or suspected of to any component of the test product or reference product;
  • Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    MC2-01 Cream

    MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).

    Drug: MC2-01 Cream

  • Active comparator
    CAL/BDP combination

    CAL/BDP ointment (w/w 0.005%/0.064%).

    Drug: CAL/BDP combination

Interventions

  • DrugMC2-01 Cream

    Drug pages: Calcipotriene · Betamethasone dipropionate

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

  • DrugCAL/BDP combination

    Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 4

  2. Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 8

  3. Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 4

  4. Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 8

  5. Maximum Plasma Concentration (Cmax) of the Metabolite MC1080

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 4

  6. Maximum Plasma Concentration (Cmax) of the Metabolite MC1080

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 8

  7. Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 4

  8. Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate

    Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

    Time frame: Week 8

Secondary outcomes

  1. Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment

    The HPA axis evaluation is based on an Adrenocorticotropic hormone \[ACTH\] challenge test, defined by a 30 minutes ACTH stimulated cortisol value. Only subject with no HPA suppression at baseline were included in the analysis. The outcome measure lists the number of subjects with HPA suppression 30 minutes after ACTH challenge

    Time frame: Week 4

  2. Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment

    The HPA challenge test were only performed on subjects that were assigned to the MC2-01 cream group. Out of a total of 32 subjects, 5 subjects were excluded from the analysis as they had HPA suppression at baseline

    Time frame: Week 8

  3. Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium

    Changes from baseline of albumin-corrected serum calcium \[mmol/L\]

    Time frame: Baseline and week 4

  4. Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium

    Changes from baseline in albumin-corrected serum calcium \[mmol/L\]

    Time frame: Baseline and week 8

  5. Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion

    Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]

    Time frame: Baseline and week 4

  6. Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion

    Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]

    Time frame: Baseline and week 8

  7. Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine

    Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)

    Time frame: Baseline and week 4

  8. Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine

    Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)

    Time frame: Baseline and week 8

07

Results

Posted Dec 24, 2019

Participant flow

First Subject First Visit: 08Feb-2018. Last Subject Last Visit: 04-Aug-2018.

Participant flow — Overall Study
MilestoneMC2-01 CreamCAL/BDP Combination
Started3231
Completed2629
Not completed62

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 4
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
pg/mLMC2-01 CreamCAL/BDP Ointment
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene30.2 (29.8 to 30.7)30.0 (30 to 30)
PrimaryMaximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 8
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
pg/mLMC2-01 Cream
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene30.0 (30.0 to 30.0)
PrimaryMaximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 4
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
pg/mLMC2-01 CreamCAL/BDP Combination
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate21.5 (19.5 to 23.7)23.1 (19.0 to 28.1)
PrimaryMaximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 8
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
pg/mLMC2-01 Cream
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate20.0 (20.0 to 20.0)
PrimaryMaximum Plasma Concentration (Cmax) of the Metabolite MC1080

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 4
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
pg/mLMC2-01 CreamCAL/BDP Ointment
Maximum Plasma Concentration (Cmax) of the Metabolite MC108029.8 (28.7 to 31.0)29.2 (29.0 to 29.3)
PrimaryMaximum Plasma Concentration (Cmax) of the Metabolite MC1080

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 8
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
pg/mLMC2-01 Cream
Maximum Plasma Concentration (Cmax) of the Metabolite MC108029.1 (29.1 to 29.1)
PrimaryMaximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 4
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
pg/mLMC2-01 CreamCAL/BDP Ointment
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate39.3 (25.8 to 59.8)38.2 (27.4 to 53.4)
PrimaryMaximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate

Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose

Time frame:
Week 8
Reported as:
Geometric mean · pg/mL
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
pg/mLMC2-01 Cream
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate26.2 (20.5 to 33.5)
SecondaryNumber of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment

The HPA axis evaluation is based on an Adrenocorticotropic hormone \[ACTH\] challenge test, defined by a 30 minutes ACTH stimulated cortisol value. Only subject with no HPA suppression at baseline were included in the analysis. The outcome measure lists the number of subjects with HPA suppression 30 minutes after ACTH challenge

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment
ParticipantsMC2-01 Cream
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment1
SecondaryNumber of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment

The HPA challenge test were only performed on subjects that were assigned to the MC2-01 cream group. Out of a total of 32 subjects, 5 subjects were excluded from the analysis as they had HPA suppression at baseline

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment
ParticipantsMC2-01 Cream
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment2
SecondaryCalcium Metabolism Evaluation in Albumin-corrected Serum Calcium

Changes from baseline of albumin-corrected serum calcium \[mmol/L\]

Time frame:
Baseline and week 4
Reported as:
Mean · mmol/L
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
mmol/LMC2-01 Cream
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium-0.00 ± 0.09
SecondaryCalcium Metabolism Evaluation in Albumin-corrected Serum Calcium

Changes from baseline in albumin-corrected serum calcium \[mmol/L\]

Time frame:
Baseline and week 8
Reported as:
Mean · mmol/L
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
mmol/LMC2-01 Cream
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium0.00 ± 0.07
SecondaryCalcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion

Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]

Time frame:
Baseline and week 4
Reported as:
Mean · mmol/day
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
mmol/dayMC2-01 Cream
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion-0.56 ± 1.69
SecondaryCalcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion

Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]

Time frame:
Baseline and week 8
Reported as:
Mean · mmol/day
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
mmol/dayMC2-01 Cream
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion-0.45 ± 1.08
SecondaryCalcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine

Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)

Time frame:
Baseline and week 4
Reported as:
Mean · mmol/g
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
mmol/gMC2-01 Cream
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine-0.23 ± 1.49
SecondaryCalcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine

Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)

Time frame:
Baseline and week 8
Reported as:
Mean · mmol/g
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
mmol/gMC2-01 Cream
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine0.00 ± 1.32

Adverse events

Collected over AEs were collected/assessed from the time of the signature of the informed consent form by the subject during the screening visit (up to 4 weeks prior to treatment), during the treatment period (up to 8 weeks) and until the final follow-up visit had occurred (up to 4 weeks following end of treatment). All AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the subject was stable. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MC2-01 Cream0/32 (0%)0/32 (0%)0/32 (0%)
CAL/BDP Combination0/31 (0%)1/31 (3.2%)0/31 (0%)
Most frequent serious events
Most frequent serious events
EventMC2-01 CreamCAL/BDP Combination
Ankle FractureMusculoskeletal and connective tissue disorders0/321/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)MC2-01 CreamCAL/BDP CombinationTotal
Mean52.8 ± 15.549.7 ± 16.251.3 ± 15.8
Sex: Female, Male
Sex: Female, Male(Participants)MC2-01 CreamCAL/BDP CombinationTotal
Female192140
Male131023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MC2-01 CreamCAL/BDP CombinationTotal
American Indian or Alaska Native101
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American224
White282856
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)MC2-01 CreamCAL/BDP CombinationTotal
United States323163
Baseline Physician's Global Assessment (PGA)
Baseline Physician's Global Assessment (PGA)(Participants)MC2-01 CreamCAL/BDP CombinationTotal
Moderate293059
Severe314
Baseline Body Surface Area (BSA)
Baseline Body Surface Area (BSA)(Percentage of psoriasis involvement)MC2-01 CreamCAL/BDP CombinationTotal
Mean23.56 ± 2.5224.09 ± 3.1323.82 ± 2.82
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)MC2-01 CreamCAL/BDP CombinationTotal
I325
II11920
III8614
IV5914
V358
VI202
08

Study locations

1 site
  • Lenus Research and Medical Group
    Sweetwater, Florida 33172, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2018, 5 months.

Results were first posted in Dec 2019, 1 year 4 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2018
First posted
Mar 13, 2018
StartActual
Feb 8, 2018
Primary completionActual
Aug 4, 2018
CompletionActual
Aug 4, 2018
Results first posted
Dec 24, 2019
Last update
Dec 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03462927
Lead sponsor
MC2 Therapeutics
Responsible party
Sponsor
First posted
Mar 13, 2018
Start date
Feb 8, 2018
Primary completion
Aug 4, 2018
Completion
Aug 4, 2018
Results posted
Dec 24, 2019
Last update
Dec 24, 2019

Study contacts

George Han
principal investigator · Department of Dermatology, Mount Sinai Beth Israel

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion